Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effectiveness of the antipsychotic medication olanzapine in treating outpatients with anorexia nervosa.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• Meets DSM-IV criteria (not including amenorrhea) for AN

• Body mass index (BMI) less than 19 kg/m2 and greater than 14 kg/m2

• Patient (or family if the patient is a minor) refuses hospitalization

• Free of psychotropic medication (4 weeks medication free for fluoxetine and antipsychotic medication; 2 weeks medication free for all others) OR on a stable dose of an SSRI or SNRI (venlafaxine) for 4 weeks before study entry

• Prior treatment of AN

Exclusion Criteria:

• Any medical or psychiatric problem requiring urgent attention and/or any significant comorbid illness not likely to benefit from proposed treatments

• Allergy to olanzapine

• Significant orthostatic high blood pressure

• Recent commencement of psychotherapy in the community

• Diabetes mellitus, with a fasting serum glucose greater than 120 mg/dL or nonfasting serum glucose greater than 140 mg/dL

• Known history of current or past jaundice

• Known history of narrow angle glaucoma

• Active substance abuse or dependence

• Schizophrenia, schizophreniform disorder, or bipolar illness

• Movement disorder or presence of tics

• History of tardive dyskinesia

• History of seizures

• Pregnant